Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma / 대한내과학회지
Korean Journal of Medicine
;
: 152-158, 2019.
Article
in Korean
| WPRIM
| ID: wpr-759927
ABSTRACT
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Organization and Administration
/
United States Food and Drug Administration
/
B-Lymphocytes
/
Receptors, Antigen
/
T-Lymphocytes
/
Biomarkers
/
Lymphoma, B-Cell
/
Lymphoma, Large B-Cell, Diffuse
/
Cell- and Tissue-Based Therapy
/
Korea
Type of study:
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS